NCT06644404View on ClinicalTrials.gov

Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 26, 2024

Primary Completion Date

December 3, 2024

Study Completion Date

April 1, 2025

Conditions
Healthy
Interventions
DRUG

DWP16001 0.3mg

1 tablet, Orally, Once daily single dose

DRUG

DWC202407 1,000mg

1 tablet, Orally, Twice daily

DRUG

DWC202408 2mg

1 tablet, Orally, Once daily single dose

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY